Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication
10.1080/21553769.2019.1622596 [DOI] [Google Scholar] Haghikia A., Yanchev G
Date published: 2021-09-24 Rated 5 out of 5 by Margie from Great Product
This narrower receptor profile explains why melanotan-1 produces strong melanogenic and anti-inflammatory effects with weaker sexual-function and appetite effects compared to its cyclic counterpart
Evidence-based treatments focus on improving function, reducing pain, and enhancing quality of life rather than seeking a cure, as fibromyalgia is a chronic condition requiring long-term management strategies
